Astellas Pharma (4503) R&D Day 2026 summary

Pipeline overview and program updates

• Achieved proof of concept for flagship assets ASP2138, ASP7317, zitidagresib (ASP3082/setidegrasib), and AT845, with phase III trials initiated or planned in PDAC, NSCLC, and gastric cancer.

• Strategic focus on immuno-oncology, targeted protein degradation, blindness/regeneration, and genetic regulation, with ongoing expansion and reprioritization.

• Terminated 21 clinical-stage programs to reallocate resources to higher-value, lower-risk assets, improving pipeline quality.

• Pipeline includes late- and early-stage programs in oncology, ophthalmology, neuromuscular, and women's health, with 12 Phase 1 FSD NMEs and 4 PoCs achieved.

Clinical trial data and development milestones

• Zitidagresib/setidegrasib (ASP3082) showed strong efficacy in phase I PDAC (ORR 58.3%, DCR 83.3%) and NSCLC (ORR 37.5%, median PFS 11.2 months); phase III trials underway or planned.

• ASP2138 achieved POC in gastric/GEJ adenocarcinoma; phase III trial targeting low to moderate Claudin 18.2 expression patients is planned.

• ASP7317 achieved POC in severe visual impairment due to geographic atrophy; phase Ib data to be presented at ARVO 2026, with global phase III development planned.

• AT-845 gene therapy for Pompe disease is under review for final POC decision, with follow-on programs advancing.

• PADCEV plus pembrolizumab improved event-free and overall survival in muscle-invasive bladder cancer (EV-304).

R&D strategy and innovation priorities

• Focus Area Approach integrates biology, modality/technology, and disease to generate multiple programs from a single scientific foundation.

• Strategic shift toward high-value, de-risked pipeline progression and enhanced productivity, targeting 10 new molecular entities to enter phase III by 2034.

• End-to-end operational model, agile practices, and investment in AI, robotics, and digital platforms have increased R&D productivity and reduced timelines.

• Data-driven portfolio review and strict discipline in project prioritization and discontinuation to maximize value and efficiency.